Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Kyle Jackson on Feb 6th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $11.62, for a total transaction of $23,240.00. Following the completion of the sale, the president now owns 2,885,138 shares of the company’s stock, valued at approximately $33,525,303.56. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total transaction of $24,800.00.

Gyre Therapeutics Stock Down 0.5 %

Shares of Gyre Therapeutics stock traded down $0.07 during trading on Thursday, hitting $12.75. 80,961 shares of the stock were exchanged, compared to its average volume of 94,851. The stock’s fifty day moving average is $11.11 and its 200 day moving average is $12.45. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its position in shares of Gyre Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after acquiring an additional 918 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in Gyre Therapeutics in the fourth quarter worth about $1,225,000. Bank of New York Mellon Corp lifted its holdings in Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after purchasing an additional 1,389 shares during the period. Barclays PLC lifted its holdings in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares during the period. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.